https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-12-15 / Cancer Immunol. Immunother. 2013 Apr;62(4):761-72
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-12-15 / Cancer Immunol. Immunother. 2013 Apr;62(4):761-722012-12-15 00:00:002019-02-15 08:49:50The immunological response and post-treatment survival of DC-vaccinated melanoma patients are associated with increased Th1/Th17 and reduced Th3 cytokine responses
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-12-01 / Clin. Exp. Immunol. 2012 Dec;170(3):291-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-12-01 / Clin. Exp. Immunol. 2012 Dec;170(3):291-92012-12-01 00:00:002019-02-15 08:48:38Enhanced therapeutic effect of B cell-depleting anti-CD20 antibodies upon combination with in-situ dendritic cell vaccination in advanced lymphoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-11-01 / Oncoimmunology 2012 Nov;1(8):1401-1403
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-11-01 / Oncoimmunology 2012 Nov;1(8):1401-14032012-11-01 00:00:002019-02-15 08:39:52Targeting cancer stem cells via dendritic-cell vaccination
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-11-01 / Clin. Exp. Immunol. 2012 Nov;170(2):167-77
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-11-01 / Clin. Exp. Immunol. 2012 Nov;170(2):167-772012-11-01 00:00:002019-02-15 08:50:42Optimizing dendritic cell vaccine for immunotherapy in multiple myeloma: tumour lysates are more potent tumour antigens than idiotype protein to promote anti-tumour immunity
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-11-01 / J. Cell. Mol. Med. 2012 Nov;16(11):2827-37
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-11-01 / J. Cell. Mol. Med. 2012 Nov;16(11):2827-372012-11-01 00:00:002019-02-15 08:39:53Complex evaluation of human monocyte-derived dendritic cells for cancer immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-10-01 / Immunotherapy 2012 Oct;4(10):995-1009
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-10-01 / Immunotherapy 2012 Oct;4(10):995-10092012-10-01 00:00:002019-02-15 08:52:14Dendritic cell-based tumor vaccinations in epithelial ovarian cancer: a systematic review
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-10-01 / Immunotherapy 2012 Oct;4(10):1011-22
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-10-01 / Immunotherapy 2012 Oct;4(10):1011-222012-10-01 00:00:002019-02-15 08:50:37Dendritic cell-based immunotherapy in mesothelioma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-09-11 / Int. J. Oncol. 2012 Nov;41(5):1601-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-09-11 / Int. J. Oncol. 2012 Nov;41(5):1601-92012-09-11 00:00:002012-09-11 00:00:00Phase I/II study of immunotherapy using tumor antigen-pulsed dendritic cells in patients with hepatocellular carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-09-01 / Cancer Immunol Immunother 2012 Sep;61(9):1415-24
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-09-01 / Cancer Immunol Immunother 2012 Sep;61(9):1415-242012-09-01 00:00:002023-03-07 13:03:07Autologous dendritic cell vaccine for estrogen receptor (ER)/progestin receptor (PR) double-negative breast cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-08-21 / Hum Vaccin Immunother 2012 Sep;8(9):1179-91
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-08-21 / Hum Vaccin Immunother 2012 Sep;8(9):1179-912012-08-21 00:00:002019-02-15 08:52:22Immunotherapy in ovarian cancer
